207 related articles for article (PubMed ID: 21739089)
1. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.
Imanishi Y; Hashimoto J; Ando W; Kobayashi K; Ueda T; Nagata Y; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Morioka T; Mori K; Miki T; Inaba M
J Bone Miner Metab; 2012 Jan; 30(1):93-9. PubMed ID: 21739089
[TBL] [Abstract][Full Text] [Related]
2. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA; Jimenez C; Huang SC; Cote GJ; Murphy WA; Gagel RF; Hoff AO
Endocr Pract; 2008 Dec; 14(9):1108-14. PubMed ID: 19158050
[TBL] [Abstract][Full Text] [Related]
4. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.
Nampei A; Hashimoto J; Hayashida K; Tsuboi H; Shi K; Tsuji I; Miyashita H; Yamada T; Matsukawa N; Matsumoto M; Morimoto S; Ogihara T; Ochi T; Yoshikawa H
J Bone Miner Metab; 2004; 22(3):176-84. PubMed ID: 15108058
[TBL] [Abstract][Full Text] [Related]
5. Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.
Zhang GX; Mizuno M; Tsuji K; Tamura M
Endocrine; 2004 Jun; 24(1):15-24. PubMed ID: 15249699
[TBL] [Abstract][Full Text] [Related]
6. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
7. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
Pereira RC; Juppner H; Azucena-Serrano CE; Yadin O; Salusky IB; Wesseling-Perry K
Bone; 2009 Dec; 45(6):1161-8. PubMed ID: 19679205
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
9. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.
Rowe PS; de Zoysa PA; Dong R; Wang HR; White KE; Econs MJ; Oudet CL
Genomics; 2000 Jul; 67(1):54-68. PubMed ID: 10945470
[TBL] [Abstract][Full Text] [Related]
10. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
11. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
12. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
Argiro L; Desbarats M; Glorieux FH; Ecarot B
Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
[TBL] [Abstract][Full Text] [Related]
13. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.
Boukpessi T; Gaucher C; Léger T; Salmon B; Le Faouder J; Willig C; Rowe PS; Garabédian M; Meilhac O; Chaussain C
Am J Pathol; 2010 Aug; 177(2):803-12. PubMed ID: 20581062
[TBL] [Abstract][Full Text] [Related]
14. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts.
Siggelkow H; Schmidt E; Hennies B; Hüfner M
Bone; 2004 Aug; 35(2):570-6. PubMed ID: 15268910
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia.
Larsson T; Zahradnik R; Lavigne J; Ljunggren O; Jüppner H; Jonsson KB
Eur J Endocrinol; 2003 Feb; 148(2):269-76. PubMed ID: 12590648
[TBL] [Abstract][Full Text] [Related]
16. MEPE Localization in the Craniofacial Complex and Function in Tooth Dentin Formation.
Gullard A; Gluhak-Heinrich J; Papagerakis S; Sohn P; Unterbrink A; Chen S; MacDougall M
J Histochem Cytochem; 2016 Apr; 64(4):224-36. PubMed ID: 26927967
[TBL] [Abstract][Full Text] [Related]
17. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
18. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
19. MEPE is a novel regulator of growth plate cartilage mineralization.
Staines KA; Mackenzie NC; Clarkin CE; Zelenchuk L; Rowe PS; MacRae VE; Farquharson C
Bone; 2012 Sep; 51(3):418-30. PubMed ID: 22766095
[TBL] [Abstract][Full Text] [Related]
20. MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Rowe PS; Kumagai Y; Gutierrez G; Garrett IR; Blacher R; Rosen D; Cundy J; Navvab S; Chen D; Drezner MK; Quarles LD; Mundy GR
Bone; 2004 Feb; 34(2):303-19. PubMed ID: 14962809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]